Kuros Reports Publication of MagnetOs Data Demonstrating Equivalence to Autologous Bone in Spinal Fusion
December 06, 2018 01:00 ET
|
Kuros Biosciences
Study should further enhance competitive positioning of MagnetOsSheep animal model is one of the most relevant preclinical models and believed to be predictive of outcomes in humans12-week fusion rate...
Kuros Biosciences Obtains US Patent Covering a Method for Producing Osteoinductive Materials
October 22, 2018 01:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today that its Dutch subsidiary, Kuros Biosciences BV, has recently been granted the US...
Kuros Biosciences Advances its Fibrin-PTH (KUR-113) Spinal Fusion Product Candidate Program
October 18, 2018 01:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today that the Company has reached a key milestone in its Fibrin-PTH (KUR-113) spinal...
Kuros Reports First Patient Treated in Randomized Controlled Trial of MagnetOs in Spinal Fusion
September 27, 2018 11:30 ET
|
Kuros Biosciences
Kuros commercial activity focused on MagnetOs in spinal fusionStudy should further enhance competitive positioning of MagnetOs SCHLIEREN (ZURICH), Switzerland, Sept. 27, 2018 (GLOBE NEWSWIRE) --...
Kuros Biosciences Appoints Strategic Advisory Board
September 25, 2018 11:30 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work...
Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration
September 13, 2018 13:09 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences, (SWX:KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone...
Kuros Biosciences Reports Results for First Half 2018
September 05, 2018 01:00 ET
|
Kuros Biosciences
Financial highlights CHF 9.7 million cash at June 30Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOsCommercial rollout in the U.S....
Kuros Biosciences Appoints Pascal Longlade as Chief Medical Officer
August 23, 2018 01:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Longlade as Chief Medical Officer, effective September...
Kuros Biosciences Reports First U.S. & UK sales of MagnetOs
July 02, 2018 01:00 ET
|
Kuros Biosciences
Commercial Roll-Out in the U.S. & Europe On Track SCHLIEREN (ZURICH), Switzerland, July 02, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) announced today it recorded the first...
Kuros Biosciences to Present Promising Clinical Case Studies with MagnetOs at Leading Spine Surgery Conference
June 19, 2018 01:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, June 19, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) will this week present results from several investigator-led clinical case studies of MagnetOs...